American Urological Association (AUA) Guideline on prostate cancer detection: process and rationale

  title={American Urological Association (AUA) Guideline on prostate cancer detection: process and rationale},
  author={Herbert Ballentine Carter},
  journal={BJU International},
  • H. Carter
  • Published 1 September 2013
  • Medicine
  • BJU International
To review the process and rationale for the American Urological Association (AUA) guideline on prostate cancer detection. The AUA guideline on detection of prostate cancer involved a systematic literature review of >300 studies that evaluated outcomes important to patients (prostate cancer, incidence/mortality, health‐related quality of life, diagnostic accuracy and harms of testing). A multidisciplinary panel interpreted the evidence and formulated statements to assist the urologist and the… 

Application of the 2013 American Urological Association early detection of prostate cancer guideline: Who will we miss?

Features of CaP in men no longer recommended for routine screening are largely equivalent to if not worse than those in screened men.

Effect of a Prostate Cancer Screening Decision Aid for African-American Men in Primary Care Settings

The DA improved men's knowledge, reduced decisional conflict, and promoted the perception of being prepared for SDM, suggesting that use of an online DA to improve SDM outcomes warrants further testing in a future trial.

Prostate Cancer for the Internist

The vast majority of men diagnosed with clinically localized prostate cancer are treated with interventional therapies despite studies demonstrating that even without treatment, prostate cancer-specific mortality is low.

Prostate cancer: what is the right message?

The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate‐specific Antigen‐era

The prevalence of unsuspected prostate cancer discovered at autopsy among 6,024 men was reviewed, and among men aged 70–79, tumor was found in 36% of Caucasians and 51% of African‐Americans.

Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.

  • G. Pron
  • Medicine, Political Science
    Ontario health technology assessment series
  • 2015
It is unlikely that the introduction of a formal PSA screening program would reduce PC mortality, and none of the RCTs found a reduction in all-cause mortality and all found a statistically significant increase in the detection of mainly low-risk, organ-confined PCs in the screening arm.

Cancer Screening in the Elderly: A Review of Breast, Colorectal, Lung, and Prostate Cancer Screening

The evidence and guidelines on breast, colorectal, lung and prostate cancer as applied to older adults are reviewed and a general framework for approaching cancer screening in older adults is provided by incorporating evidence-based guidelines, patient preferences, and patient life expectancy estimates into shared screening decisions.



Comparative Effectiveness of Alternative Prostate-Specific Antigen–Based Prostate Cancer Screening Strategies

Compared with standard screening, PSA screening strategies that use higher thresholds for biopsy referral for older men and that screen men with low PSA levels less frequently can reduce harms while preserving lives.

Mortality results from a randomized prostate-cancer screening trial.

After 7 to 10 years of follow-up, the rate of death from prostate cancer was very low and did not differ significantly between the two study groups.

Prostate-cancer mortality at 11 years of follow-up.

Analyses after 2 additional years of follow-up consolidated the previous finding that PSA-based screening significantly reduced mortality from prostate cancer but did not affect all-cause mortality.

Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement

  • V. Moyer
  • Medicine
    Annals of Internal Medicine
  • 2012
The USPSTF recommends against PSA-based screening for prostate cancer (grade D recommendation), which applies to men in the general U.S. population, regardless of age.

Prostate cancer mortality in the Finnish randomized screening trial.

At 12 years, a relatively conservative screening protocol produced a small, non-statistically significant PC-specific mortality reduction in the Finnish trial, at the cost of moderate overdiagnosis.

A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices.

Benefits and harms of PSA screening vary substantially with age and familial risk, and higher-risk men have more prostate cancer deaths averted but also more prostate cancers diagnosed and related harms.

Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.

Data suggest that for men with no cancer suspected on digital rectal examination, a PSA level of 4.0 to 5.0 ng/mL is an acceptable range for maintaining the detection of curable prostate cancer and a 2-year PSA testing interval is not likely to miss a curable cancer when the initial PSAlevel is less than 2.0 Ng/mL.